УИЛСОН Тимоти Р. (US),КОЕППЕН Хартмут (US),МЕРЧАНТ Марк (US),СЕТТЛМАН Джеффри (US)
申请号：
RU2014114617/10
公开号：
RU2014114617A
申请日:
2012.09.19
申请国别(地区):
RU
年份:
2015
代理人:
摘要：
1. A method of treating a patient with a malignant tumor, comprising administering an effective amount of a B-raf antagonist and a c-met antagonist. A method of treating a patient with a malignant tumor, which is characterized by an increased likelihood of developing resistance to a B-raf antagonist, comprising administering an effective amount of a B-raf antagonist and a c-met antagonist. 3. A method of increasing and / or restoring sensitivity to a B-raf antagonist, comprising administering to a cancer patient an effective amount of a B-raf antagonist and a c-met antagonist. 4. A method of increasing the sensitivity period to a B-raf antagonist, comprising administering to a patient with a malignant tumor an effective amount of a B-raf antagonist and a c-met antagonist. A method of treating a patient with a B-raf antagonist resistant malignant tumor, comprising administering an effective amount of a B-raf antagonist and a c-met antagonist. A method for increasing the duration of a response to a B-raf antagonist, comprising administering an effective amount of a B-raf antagonist and a c-met antagonist. A method for slowing down or preventing a patient from developing a malignant tumor with HGF-mediated resistance to a B-raf antagonist, comprising administering an effective amount of a B-raf antagonist and a c-met antagonist. The method of claim 7, wherein the patient's malignant tumor has been shown to express a B-raf biomarker. The method of claim 8, wherein the B-raf biomarker is B-raf V600.10. The method of claim 8, wherein the B-raf biomarker is a B-raf V600E.11. The method according to any one of paragraphs. 8-10, in which the expression of the biomarker of mutant B-raf in malignancy1. Способ лечения пациента со злокачественной опухолью, предусматривающий введение эффективного количества антагониста B-raf и антагониста c-met.2. Способ лечения пациента со злокачественной опухолью, которая характеризуется повышенной вероятностью развития устойчивости к антагонис
